Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032747 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
NCT00032747 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 338 participants.
The verdict
NCT00032747, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and \<137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the total duration of the double-blind treatment period is 120 days.
Interventions
- DRUG Vasopressin V2 Receptor Antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032747
The ClinicalTrials.gov registry entry for NCT00032747 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vasopressin V2 Receptor Antagonist is the first listed.
NCT00032747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00032747 about?
NCT00032747 is a clinical study titled "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).". This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and \<137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the ...
What is the current status of trial NCT00032747?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2001-08. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00032747?
The interventions under investigation include: Vasopressin V2 Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT00032747?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.